Search clinical trials for: Triweekly Cetuximab

Total 1026 results

Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Colorectal Cancer | Lung Cancer | Dermatologic Complications | Therapy-related Toxicity

United States
University of Colorado, Denver
Vasgene Therapeutics, Inc

Completed

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Squamous Cell Carcinoma of Head and Neck

United States
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Eli Lilly and Company

Completed

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Colorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung Cancer

United States, Japan, Australia, France
Hoffmann-La Roche

Completed

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Breast Cancer | Solid Tumor | Cancer of Head and Neck

Spain, United States, Belgium, Denmark, France, United Kingdom, Canada, Netherlands, Italy
Trans Tasman Radiation Oncology Group

Active, not recruiting

Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

Belgium, Spain, France, Germany, United States, United Kingdom, Italy, Australia, Poland
Translational Genomics Research Institute
Eli Lilly and Company

Withdrawn

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Metastatic Colorectal Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Colorectal Carcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Squamous Cell Carcinoma of the Head and Neck

Brazil, Italy, United Kingdom, United States, Hong Kong, France, Netherlands, Germany, Argentina, Canada, Japan, Korea, Republic of, Spain, Switzerland, Taiwan
AIO-Studien-gGmbH

Completed

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (AVETUX)

Metastatic Colorectal Cancer

Germany
The University of Texas Health Science Center at...
University of Pittsburgh

Completed

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma

United States
Amgen

Completed

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Sweden, Belgium, Czechia, Italy, Poland, United States, France, Korea, Republic of, Peru, Philippines, Russian Federation, United Kingdom, China, Canada, Israel, Lithuania, Australia, South Africa, Bulgaria, Romania, Taiwan, Latvia, Serbi... and more
Armando Santoro, MD

Completed

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Colorectal Cancer Metastatic | C-met Overexpression

Italy
Groupe Oncologie Radiotherapie Tete et Cou
AIO-Studien-gGmbH; Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Completed

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (TPExtreme)

Head and Neck Squamous Cell Carcinoma

France, Germany, Spain
GlaxoSmithKline
MedImmune LLC

Completed

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Neoplasms

United States, Canada, Australia
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (ELANFIT)

Metastatic or Recurrent Head and Neck Squamous Cell Cancer

France
Federation Francophone de Cancerologie Digestive

Active, not recruiting

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)

Metastatic Colorectal Cancer | MSI

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (ACE-Lung)

Non Small Cell Lung Cancer

France
Weill Medical College of Cornell University

Terminated

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Glioblastoma Multiforme | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brain Stem Glioma | Pilomyxoid Astrocytoma | Glioma of Brainstem | Fibrillary Astrocytoma of Brain | Mixed Oligodendroglioma-Astrocytoma

United States
Hadassah Medical Organization
Merck Serono International SA

Terminated

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon

Israel
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology; Cancer and Leukemia Group B; North...

Completed

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Cancer | Radiation Toxicity

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Esophageal Cancer

Canada, United States
Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Squamous Non-Small Cell Lung Cancer

Spain, Hungary, Serbia
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (HNO-2)

Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditions

Austria
University of Heidelberg Medical Center
iOMEDICO AG

Completed

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) (HICARE)

Head and Neck Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (CHANGE2)

Carcinoma, Squamous Cell of Head and Neck

Germany
University of Campania "Luigi Vanvitelli"

Completed

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | RAS Wild Type

Italy
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
NSABP Foundation Inc
Puma Biotechnology, Inc.

Active, not recruiting

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Metastatic Colorectal Cancer

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Colorectal Cancer Metastatic | mCRC

United States
UNICANCER

Completed

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (TIME)

Metastatic Colorectal Cancer

France
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Squamous Cell Carcinoma of the Head and Neck

Spain
University of Texas Southwestern Medical Center

Completed

Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer (INFIELD)

Head and Neck Cancer | Carcinoma, Squamous Cell | Neoplasms, Oral | Neoplasms, Pharyngeal

United States
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; University of Colorado... and other collaborators

Completed

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Brain Cancer

United States, Canada
Swiss Group for Clinical Cancer Research

Completed

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

Switzerland
David A. Clump, MD, PhD

Completed

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Boston Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Terminated

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Alcohol Use Disorder

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type

United States
Fox Chase Cancer Center

Terminated

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Colorectal Neoplasms

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Completed

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Colon Cancer

United States
UNICANCER

Completed

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Colorectal Cancer

France
UNICANCER

Completed

Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (SULTAN)

Colorectal Cancer Metastatic

France
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Eli Lilly and Company

Terminated

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States, Australia
Fate Therapeutics

Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid Tumor

United States

Search clinical trials for: Triweekly Cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations